PDF(Pubmed)
Abstract：
OBJECTIVE: To analyze the efficacy of hydroxyethyl starch (HES) combined with Ulinastatin (Uti) in the treatment of newborns with capillary leak syndrome (CLS).
METHODS: A total of 60 newborns with CLS admitted to four hospitals were selected as the study subjects, and were randomly divided into the control group (n = 30) and the observation group (n = 30) in accordance with the random number table. The control group was treated with HES alone, while the observation group was treated with Uti combined with HES.
RESULTS: At 5 d after treatment, the incidence rates of systemic edema and pulmonary edema, the levels of CRP, NE, and BUN, and the duration for the improvement of systemic edema, pulmonary edema and NICU hospital stay in the control group were superior to those in the observation group, while the 24-h urine output, PaO2 and MAP levels, the levels of A, SCr, ALT, and IL-10 in the observation group were superior to those in the control group (P < 0.05). After 3 months of follow-up after treatment, the mortality rate of newborns in the observation group (13.33%) was lower than that in the control group (36.67%) (P < 0.05).
CONCLUSIONS: HES combined with Uti can effectively alleviate edema, control inflammatory levels, and improve hepatic and renal functions and neonatal survival rate of newborns with CLS.
METHODS: A total of 60 newborns with CLS admitted to four hospitals were selected as the study subjects, and were randomly divided into the control group (n = 30) and the observation group (n = 30) in accordance with the random number table. The control group was treated with HES alone, while the observation group was treated with Uti combined with HES.
RESULTS: At 5 d after treatment, the incidence rates of systemic edema and pulmonary edema, the levels of CRP, NE, and BUN, and the duration for the improvement of systemic edema, pulmonary edema and NICU hospital stay in the control group were superior to those in the observation group, while the 24-h urine output, PaO2 and MAP levels, the levels of A, SCr, ALT, and IL-10 in the observation group were superior to those in the control group (P < 0.05). After 3 months of follow-up after treatment, the mortality rate of newborns in the observation group (13.33%) was lower than that in the control group (36.67%) (P < 0.05).
CONCLUSIONS: HES combined with Uti can effectively alleviate edema, control inflammatory levels, and improve hepatic and renal functions and neonatal survival rate of newborns with CLS.
摘要：
目的：分析羟乙基淀粉(HES)联合乌司他丁(Uti)治疗新生儿毛细血管渗漏综合征(CLS)的疗效。
方法：选取四所医院收治的60例CLS新生儿作为研究对象，按照随机数字表法随机分为对照组(n=30)和观察组(n=30)。对照组采用单纯HES治疗,观察组采用Uti联合HES治疗。
结果：治疗后5d，全身水肿和肺水肿的发生率，CRP的水平，NE,和BUN,和全身水肿改善的持续时间，对照组肺水肿和NICU住院时间均优于观察组,而24小时的尿量，PaO2和MAP水平,A的水平,SCr,ALT,观察组IL-10水平明显优于对照组(P<0.05)。治疗后3个月随访,观察组新生儿死亡率(13.33%)低于对照组(36.67%)(P<0.05)。
结论：HES联合Uti能有效缓解水肿，控制炎症水平，改善CLS新生儿的肝肾功能和新生儿存活率。
方法：选取四所医院收治的60例CLS新生儿作为研究对象，按照随机数字表法随机分为对照组(n=30)和观察组(n=30)。对照组采用单纯HES治疗,观察组采用Uti联合HES治疗。
结果：治疗后5d，全身水肿和肺水肿的发生率，CRP的水平，NE,和BUN,和全身水肿改善的持续时间，对照组肺水肿和NICU住院时间均优于观察组,而24小时的尿量，PaO2和MAP水平,A的水平,SCr,ALT,观察组IL-10水平明显优于对照组(P<0.05)。治疗后3个月随访,观察组新生儿死亡率(13.33%)低于对照组(36.67%)(P<0.05)。
结论：HES联合Uti能有效缓解水肿，控制炎症水平，改善CLS新生儿的肝肾功能和新生儿存活率。
